Cardiac hypertrophy in neonatal nephrectomized rats: The role of the sympathetic nervous system

Pediatric Nephrology

Volumn 24, Issue 2, 2009, Pages 367-377

  Ghosh, Siddhartha S ^a   Krieg, Richard J ^a   Sica, Domenic A ^a   Wang, Ruipeng ^a   Fakhry, Itaf ^a   Gehr, Todd ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Remnant kidney; Renalase; Signaling

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; CATECHOLAMINE; CREATININE; G PROTEIN COUPLED RECEPTOR KINASE 2; NITROGEN; NORADRENALIN; NORADRENALIN TRANSPORTER; PROTEIN KINASE B; UREA;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME METABOLISM; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; KIDNEY INJURY; MALE; MEAN ARTERIAL PRESSURE; NEPHRECTOMY; NEWBORN; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; UREA BLOOD LEVEL;

ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOMEGALY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HYPERTENSION, RENAL; KIDNEY FAILURE; MALE; NEPHRECTOMY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; ORGAN SIZE; PREGNANCY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 58149156562     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-0978-8     Document Type: Article

References (63)

1. O'Regan S (1984) Cardiovascular abnormalities in paediatric patients with ESRD. In: Fine RN, Gruskin AB (eds) End-stage renal disease in children. Saunders, Philadelphia, pp 359-374
2. Scharer K, Ulmer HE (1985) Cardiovascular complications of renal failure. In: Holliday MA, Barratit TM, Vernier RL (eds) Pediatric nephrology (2nd edn). Williams and Wilkins, Baltimore, pp 887-896
3. Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2006) Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 2149:671-675
4. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS (2002) Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359
5. Leineweber K, Heinroth-Hoffmann I, Pönicke K, Abraham G, Osten B, Brodde OE (2002) Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol 13:117-124
6. Mann JF, Jakobs KH, Riedel J, Ritz E (1986) Reduced chronotropic responsiveness of the heart in experimental uremia. Am J Physiol 250:H846-H852
7. Meggs LG, Ben-Ari J, Gammon D, Choudhury M, Goodman AI (1986) Effect of chronic uremia on the cardiovascular alpha 1 receptor. Life Sci 39:169-179
8. Kohout TA, Lefkowitz RJ (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63:9-18
9. Slotkin TA, Saleh JL, Zhang J, Seidler FJ (1996) Ontogeny of adrenoceptor/adenylyl cyclase desensitization mechanisms: The role of neonatal innervation. Brain Res 742:317-328
10. Garofolo MC, Seidler FJ, Auman JT, Slotkin TA (2002) Adrenergic modulation of muscarinic cholinergic receptor expression and function in the developing heart. Am J Physiol 282:R1356-R1363
11. Li F, Wang X, Capasso JM, Gerdes AM (1996) Rapid transition of cardiomyocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 28:1737-1746
12. Slotkin TA, Smith PG, Lau C, Bareis DL (1980) Functional aspects of development of catecholamine biosynthesis and release in the sympathetic nervous system. In: Parvez H, Parvez S (eds) Biogenic amines in development. Elsevier/North-Holland, Amsterdam, pp 29-48
13. Deskin R, Mills E, Whitmore WL, Seidler FJ, Slotkin TA (1980) Maturation of sympathetic neurotransmission in the rat heart. VI. The effect of neonatal central catecholaminergic lesions. J Pharmacol Exp Ther 215:342-347
14. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, Anversa P (2001) Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 344:1750-1757
15. Iaccarino G, Dolber PC, Lefkowitz RJ, Koch WJ (1999) Beta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: Regulation by beta- but not alpha1-adrenergic stimulation. Hypertension 33:396-401
16. Dhein S, Röhnert P, Markau S, Kotchi-Kotchi E, Becker K, Poller U, Osten B, Brodde OE (2000) Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Coll Cardiol 36:608-617
17. Briest W, Rassler B, Deten A, Zimmer HG (2003) Norepinephrine-induced cardiac hypertrophy and fibrosis are not due to mast cell degranulation. Mol Cell Biochem 252:229-237
18. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 342:541-549
19. Perrino C, Rockman HA (2007) Reversal of cardiac remodeling by modulation of adrenergic receptors: A new frontier in heart failure. Curr Opin Cardiol 22:443-449
20. Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of beta-adrenergic signaling in heart failure? Circ Res 93:896-906
21. Osadchii OE (2007) Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: Pathophysiological aspects. Heart Fail Rev 12:66-86
22. Penela P, Murga C, Ribas C, Tutor AS, Peregrín S, Mayor F (2006) Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res 69:46-56
23. Choi DJ, Koch WJ, Hunter JJ, Rockman HA (1997) Mechanism of b-adrenergic receptor desensitization in cardiac hypertrophy is increased b-adrenergic receptor kinase. J Biol Chem 272:17223-17229
24. Leineweber K, Rohe P, Beilfuss A, Wolf C, Sporkmann H, Bruck H, Jakob HG, Heusch G, Philipp T, Brodde OE (2005) G-protein-coupled receptor kinase activity in human heart failure: Effects of beta-adrenoceptor blockade. Cardiovasc Res 66:512-519
25. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S (2003) Phosphoinositide 3-kinase(p110a) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100:12355-12360
26. Wakatsuki T, Schlessinger J, Elson EL (2004) The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci 29:609-617
27. Krieg RJ, Chan W, Lin KC, Kuemmerle NB, Veldhuis JD, Chan JC (2002) Growth hormone and growth hormone-related mRNA in uremic rats: Effect of a growth hormone secretagogue. Pediatr Nephrol 17:585-590
28. Rocha-Singh KJ, Honbo NY, Karliner JS (1991) Hypoxia and glucose independently regulate the beta-adrenergic receptor-adenylate cyclase system in cardiac myocytes. J Clin Invest 88:204-213
29. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, Schoolwerth AC (2003) PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: Role of MAP kinase. Kidney Int 64:52-62
30. Ghosh S, Sica D, Schoolwerth AC, Quigg RJ, Haas M, Fakhry I, Gehr TW (2002) The role of the renin-angiotensin system in cholesterol and puromycin mediated renal injury. Am J Med Sci 324:296-304
31. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir GV (2005) Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 115:1275-1280
32. Yamaguchi N, Takahashi N, Xu L, Smithies O, Meissner G (2007) Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. J Clin Invest 117:1344-1353
33. Callanan EY, Lee EW, Tilan JU, Winaver J, Haramati A, Mulroney SE, Zukowska Z (2007) Renal and Cardiac Neuropeptide Y (NPY) and NPY Receptors in a Rat Model of Congestive Heart Failure. Am J Physiol Renal Physiol 293:1811-1817
34. Strand AH, Gudmundsdottir H, Os I, Smith G, Westheim AS, Bjørnerheim R, Kjeldsen SE (2006) Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens 24:905-913
35. Rascher W, Schömig A, Kreye VA, Ritz E (1982) Diminished vascular response to noradrenaline in experimental chronic uremia. Kidney Int 1:20-27
36. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E (2000) Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11:1469-1478
37. Goldstein DS (1988) Plasma catecholamines and essential hypertension: An analytical review. Hypertension 5:86-99
38. Esler M, Kaye D (2000) Measurement of sympathetic nervous system activity in heart failure: The role of norepinephrine kinetics. Heart Fail Rev 5:17-25
39. Woodcock EA (2007) Roles of a1a- and a1b-adrenoceptors in heart: insights from studies of genetically modified mice. Clin Exp Pharmacol Physiol 34:884-888
40. Anderson D, Campbell AM, Feldman M, White R, Roden W, Minobe MF, Khan P, Larrabee M, Wollmering JD, Port F (1994) Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation 90:1225-1238
41. Bazan A, Van de Velde E, Fraeyman N (1994) Effect of age on beta-receptors, Gs alpha- and Gi alpha- proteins in rat heart. Biochem Pharmacol 48:479-486
42. Tyralla K, Amann K (2003) Morphology of the heart and arteries in renal failure. Kidney Int 84:S80-S83
43. Ferchland A, Rettkowski O, Pönicke K, Deuber HJ, Osten B, Brodde OE (1998) Effects of uremic plasma on alpha- and beta-adrenoceptor subtypes. Nephron 80:46-50
44. Koch WJ (2004) Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Mol Cell Biochem. 263:5-9
45. Brodde OE, Bruck H, Leineweber K (2006) Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 100:323-337
46. Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212
47. Eckhart AD, Ozaki T, Tevaearai H, Rockman HA, Koch WJ (2002) Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol 61:749-758
48. Kimball KA, Cornett LE, Seifen E, Kennedy RH (1991) Aging changes in cardiac alpha 1-adrenoceptor responsiveness and expression. Eur J Pharmacol 208:231-238
49. Chalothorn D, McCune DF, Edelmann SE, García-Cazarin ML, Tsujimoto G, Piascik MT (2002) Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol 61:1008-1016
50. Fonseca MI, Button DC, Brown RD (1995) Agonist regulation of _1B-adrenergic receptor subcellular distribution and function. J Biol Chem 270:8902-8909
51. Wang J, Zheng J, Anderson JL, Toews ML (1997) A mutation in the hamster a1B-adrenergic receptor that differentiates two steps in the pathway of receptor internalization. Mol Pharmacol 52:306-313
52. Mahan LC, McKernan RM, Insel PA (1987) Metabolism of alpha- and beta-adrenergic receptors in vitro and in vivo. Annu Rev Pharmacol Toxicol 27:215-235
53. Akhter SA, Milano CA, Shotwell KF, Cho MC, Rockman HA, Lefkowitz RJ, Koch WJ (1997) Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of beta-adrenergic signaling. J Biol Chem 272:21253-21259
54. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG (2002) Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens. 20:3-9
55. Proud CG (2004) Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63:403-413
56. Xiao L, Pimental DR, Amin JK, Singh KSDB, Sawyer DB, Colucci WS (2001) MEK1/2-ERK1/2 mediates a1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33:779-787
57. Kodama H, Fukuda K, Pan J, Sano M, Takahashi T, Kato T, Makino S, Manabe T, Murata M, Ogawa S (2000) Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol 279:H1635-H1644
58. Thorburn J, Frost JA, Thorburn A (1994) Mitogen-activated protein kinases mediate changes in gene expression but not cytoskeletal organisation associated with cardiac muscle hypertrophy. J Cell Biol 126:1565-1572
59. Silberbach M, Gorenc T, Hershberger RE, Stork PJ, Steyger PS, Roberts CT (1999) Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J Biol Chem 274:24858-24864
60. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99:12333-12338
61. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R, Rosenzweig A (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896-22901
62. Guo J, Sabri A, Elouardighi H, Rybin V, Steinberg SF (2006) Alpha1-adrenergic receptors activate AKT via a Pyk2/PDK-1 pathway that is tonically inhibited by novel protein kinase C isoforms in cardiomyocytes. Circ Res 99:1367-1375
63. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker AJ, Foster E, Grossman W, Simpson PC (2006) Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 116:1005-1015